Northwestern Mutual Wealth Management Co. Buys 7,059 Shares of Abbott Laboratories $ABT

Northwestern Mutual Wealth Management Co. increased its position in Abbott Laboratories (NYSE:ABT) by 2.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 255,295 shares of the healthcare product maker’s stock after purchasing an additional 7,059 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Abbott Laboratories were worth $23,165,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ABT. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter worth $25,000. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories in the 4th quarter worth about $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $26,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Down 0.5%

Shares of ABT stock opened at $108.29 on Friday. The stock has a fifty day simple moving average of $104.43 and a two-hundred day simple moving average of $100.12. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The firm has a market capitalization of $187.38 billion, a PE ratio of 35.05, a PEG ratio of 2.02 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same quarter in the prior year, the company posted $1.26 earnings per share. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 81.55%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ABT shares. The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Piper Sandler reiterated an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. UBS Group dropped their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.